NewAmsterdam Pharma Announces Inducement Grants per Nasdaq Rule 5635(c)(4)

June 7, 2024 -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a clinical biopharmaceutical company focusing on the development of oral, non-statin medications for cardiovascular disease (CVD) patients with elevated low-density lipoprotein cholesterol (LDL-C), has made a significant announcement. The Compensation Committee of the company’s Board of Directors has approved the distribution of inducement share options for a total of 90,000 ordinary shares to five newly hired non-executive employees. These share options serve as an incentive for these new employees to join NewAmsterdam, as part of the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the "2024 Inducement Plan") and in compliance with Nasdaq Listing Rule 5635(c)(4).

The share options have been granted with an exercise price of $18.92 per share, matching the closing price of the Company’s ordinary shares on the Nasdaq Stock Market on June 3, 2024, the grant date. These options will vest over a period of four years, with 25% vesting on the first anniversary of the vesting commencement date, and the remaining 75% vesting in 36 equal monthly installments, provided the employees remain with NewAmsterdam through these vesting dates. The options are governed by the terms and conditions set forth in the 2024 Inducement Plan and the associated option award agreements.

NewAmsterdam Pharma is a late-stage biopharmaceutical company dedicated to enhancing patient care in populations suffering from metabolic diseases where existing therapies fall short in efficacy or tolerability. The company is addressing a notable gap in the market for a safe, well-tolerated, and convenient therapy to lower LDL-C levels.

NewAmsterdam is currently conducting multiple phase 3 clinical trials to evaluate the efficacy of obicetrapib, an oral, low-dose, once-daily CETP inhibitor. This medication is being tested both as a standalone therapy and in combination with ezetimibe, another LDL-C lowering agent. The goal is to provide an effective adjunct therapy to statins for patients at risk of CVD who do not respond adequately or cannot tolerate existing therapies.

The company's mission is to meet the pressing need for more effective and better-tolerated treatments for high LDL-C levels, a significant risk factor for cardiovascular disease. Through its ongoing research and development efforts, NewAmsterdam aims to offer new therapeutic options that can improve the quality of life for patients.

By incentivizing new hires with share options, NewAmsterdam not only attracts talented professionals but also aligns their interests with the company’s long-term goals. This strategic move underscores the company's commitment to advancing its pipeline of innovative treatments and achieving sustained growth.

The recent grant of share options is a testament to NewAmsterdam's forward-thinking approach and dedication to building a robust team capable of driving the company’s mission forward. As the phase 3 trials for obicetrapib progress, there is potential for significant advancements in the treatment of CVD, offering hope to patients who have limited options with current therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!